Developing technology that meets the acute stroke challenge head on.
Every second counts in acute stroke care, and delays in diagnosis can mean the difference between recovery and lifelong disability. At Wellumio, we're flipping the script - instead of moving patients to the scanner, we bring the scanner to the patient, delivering critical imaging exactly when and where it's needed. By eliminating barriers to timely stroke diagnosis, Wellumio empowers healthcare professionals to meet the golden hour challenge head-on.
Time lost is brain lost
Benefits of stroke reperfusion therapy decreases
rapidly with time.
Odds of disability-free survival are highest when therapy begin
within the first golden-hour of symptom onset.
anywhere in a clinical facility.
3
2.5
2
1.5
1
Odds of disability-free survival
0-1.5
1.5-3
3-4.5
4.5-6
Symptom Onset to Treatment Time (Hours)
But <5% receive treatment within the golden-hour.
.png)
The Waiting Game: When Imaging Delays Cost Lives
For decades, stroke care has revolved around transporting patients to scanners - adding delays, consuming resources, and creating bottlenecks in an already time-sensitive process. When every second matters, these delays don't just slow treatment - they cost neurons, function, and lives.
Current paradigm
Flipping the Script:
From Moving Patients to Moving Technology
At Wellumino, we're turning the traditional paradigm on its head. Instead of moving patients to imaging, we bring the scanner to them, delivering critical information to clinicians right at the bedside. For hospitals with limited resources, this is a game changer. For patients on the edge of life and death, it's a lifeline.
Bring technology to the patient
Revolutionary Portability
Point of care imaging within minutes, anywhere in a clinical facility.
Serial Imaging
Monitoring of patients with dynamic clinical conditions.
Tablet Driven Control
Intuitive interface built into the device
for a seamless imaging experience
Flexible Deployment
Operates on batteries or standard
outlets for versatile usage.
Trusted Biomarkers
T1, T2, T2 Flair, DWI and perfusion contrasts.
Small Footprint
Reduced footprint allows for easier
navigation and storage within any
clinical facility
Enhanced by AI, axana® is a mobile
stroke finder
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis elementum, tellus quis hendrerit luctus, tortor mauris sodales eros, non egestas dolor erat eu velit. Aenean sed pretium augue. Suspendisse potenti. Ut tristique po
The axana® Stroke-GPS engine integrates AI to rapidly identify
strokes, enabling timely diagnosis and interventions.
Existing modality: MRI
New modality: Pulsed Gradient Free Mapping
axana
2024
Gen 2
2023
Gen 1
2019
Mole
2006
High Field MRI
Low Field MRI
LowField MRI
Low Field MRI
Magnetic Resonance
High Field MRI
Shared origins,
different evolutionary paths.
MRI is the gold standard modality for stroke diagnosis, but its size, complexity, and infrastructure demands limit its accessibility. Axana® was designed to break these barriers.
At its core is Pulsed Gradient Free Mapping (PGFM) —a fresh approach to harnessing the power of magnetic resonance physics. Unlike conventional MRI, which relies on gradient encoding, PGFM draws inspiration from compact and efficient industrial magnetic resonance techniques. After a decade of research and development, we reengineered these methods for medical imaging, enabling brain scans without pulsed gradients. The result? A portable, fast, and simple system that brings stroke detection where and when it's needed most.
Compare Us Against the Competition
All of the above tells the story of our technology development and how we have created what we have, we also realize that not all technologies are equal it's really a matter of selecting the right tool for the job. With this in mind we feel it's good to compare what one is doing to others, competition so to speak. It helps us assess our strengths and weaknesses.
